1
|
Seo A, Chang AY. A systematic review of the social impact of diseases in Nordic countries. Scand J Public Health 2024:14034948231217365. [PMID: 38166481 DOI: 10.1177/14034948231217365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2024]
Abstract
BACKGROUND We review the literature on the social impacts of diseases, defined as the social consequences of having a disease on the people around the patient, such as spouses, caregivers and offspring. The two objectives of this study are to summarise the social outcomes commonly associated with diseases and to compare the social impact across a range of diseases. METHODS A systematic review of the social impact of disease in Nordic countries was conducted using PubMed, PsycINFO and Google Scholar (PROSPERO registration number CRD42022291796). All articles that met the inclusion criteria were reviewed. We tabulated all outcomes and diseases studied, and synthesised the evidence based on the perspectives of patients, spouse/caregiver and offspring. RESULTS A total of 135 studies met the eligibility criteria, covering 76 diseases and 39 outcomes. From the patient's perspective, diseases impact divorce and marriage rates, social functioning, likelihood of committing a crime and being a victim of crime. From the caregiver's perspective, diseases affect their health-related quality of life and physical and psychological health. From the offspring's perspective, diseases impact their development, health and social adversities in later life. Diseases generally had negative social impacts, but there were some diseases associated with positive impacts. CONCLUSIONS The review provides a useful summary and gross comparison of the social impact of different diseases. The social impact of diseases can be large and significant. Thus, it should be considered when policymakers are setting priorities across disease areas.
Collapse
Affiliation(s)
- Ahreum Seo
- Department of Public Health, University of Southern Denmark, Denmark
| | - Angela Y Chang
- Danish Institute for Advanced Study, University of Southern Denmark, Denmark
- Department of Clinical Research, University of Southern Denmark, Denmark
- Interdisciplinary Centre on Population Dynamics (CPop), University of Southern Denmark, Denmark
| |
Collapse
|
2
|
Mortensen HR, Populaire P, Hoffmann L, Moeller DS, Appelt A, Nafteux P, Muijs CT, Grau C, Hawkins MA, Troost EGC, Defraene G, Canters R, Clarke CS, Weber DC, Korevaar EW, Haustermans K, Nordsmark M, Gebski V, Achiam MP, Markar SR, Radhakrishna G, Berbee M, Scartoni D, Orlandi E, Doyen J, Gregoire V, Crehange G, Langendijk J, Lorgelly P, Blommenstein HM, Byskov CS, Ehmsen ML, Jensen MF, Freixas GV, Bütof R. Proton versus photon therapy for esophageal cancer - A trimodality strategy (PROTECT) NCT050555648: A multicenter international randomized phase III study of neoadjuvant proton versus photon chemoradiotherapy in locally advanced esophageal cancer. Radiother Oncol 2024; 190:109980. [PMID: 37935284 DOI: 10.1016/j.radonc.2023.109980] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2023] [Revised: 10/29/2023] [Accepted: 10/29/2023] [Indexed: 11/09/2023]
Affiliation(s)
- H R Mortensen
- Danish Center for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Faculty of Health Sciences, Aarhus University, Aarhus, Denmark
| | - P Populaire
- University Hospitals Leuven, Department of Radiation Oncology, Belgium; KU Leuven- University of Leuven, Department of Oncology, Laboratory of Experimental Radiotherapy, Leuven, Belgium
| | - L Hoffmann
- Department of Oncology and Medical Physics, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Faculty of Health Sciences, Aarhus University, Aarhus, Denmark
| | - D S Moeller
- Department of Oncology and Medical Physics, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Faculty of Health Sciences, Aarhus University, Aarhus, Denmark
| | | | - P Nafteux
- University Hospitals Leuven, Department of Thoracic Surgery, Belgium
| | - C T Muijs
- Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands
| | - C Grau
- Danish Center for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark
| | - M A Hawkins
- Department of Medical Physics and Biomedical Engineering, University College London, London, UK
| | - E G C Troost
- Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, and Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology - OncoRay Helmholtz-Zentrum Dresden-Rossendorf, Germany
| | - G Defraene
- KU Leuven- University of Leuven, Department of Oncology, Laboratory of Experimental Radiotherapy, Leuven, Belgium
| | - R Canters
- Department of Radiation Oncology (Maastro), GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, the Netherlands
| | - C S Clarke
- Research Dept. of Primary Care and Population Health, University College London, London, UK
| | - D C Weber
- Center for Proton Therapy, Paul Scherrer Institut, Villigen, Switzerland; Radiation Oncology Department, University Hospital Zurich, Zurich, Switzerland
| | - E W Korevaar
- Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands
| | - K Haustermans
- University Hospitals Leuven, Department of Radiation Oncology, Belgium; KU Leuven- University of Leuven, Department of Oncology, Laboratory of Experimental Radiotherapy, Leuven, Belgium
| | - M Nordsmark
- Department of Oncology and Medical Physics, Aarhus University Hospital, Aarhus, Denmark
| | - Val Gebski
- NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia
| | - M P Achiam
- Dept. Surgery and Transplantation, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
| | - Sheraz R Markar
- Department of General Surgery, Oxford University Hospitals, Oxford, UK; Nuffield Department of Surgery, University of Oxford, Oxford, UK
| | | | - Maaike Berbee
- Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands
| | - Daniele Scartoni
- Proton Therapy Center, Azienda Provinciale per i Servizi Sanitari, Trento, Italy
| | - Ester Orlandi
- National Center for Oncological Hadrontherapy (CNAO), Radiation Oncology Clinical Department, Pavia, Italy
| | | | | | - Gilles Crehange
- PSL Research University, RadiationOncology Department, Institut Curie, Paris/Orsay, France
| | - Johannes Langendijk
- Department of Radiation Oncology, UniversityMedicalCentreGroningen, Groningen, The Netherlands
| | - Paula Lorgelly
- University of Auckland, Waipara Taumata Rau, Auckland, New Zealand
| | - Hedwig M Blommenstein
- Erasmus School of Health Policy and Management, Erasmus University Rotterdam, P.O. Box 1738, Rotterdam, 3000 DR, The Netherlands; Erasmus Centre for Health Economics Rotterdam, Erasmus University, Rotterdam, The Netherlands
| | - Camilla S Byskov
- Department of Oncology and Medical physics, Aarhus University Hospital, Aarhus, Denmark
| | - Mai L Ehmsen
- Danish Center for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark
| | | | - Gloria Vilches Freixas
- Maastro Proton Therapy, Department of Radiation Oncology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
| | - Rebecca Bütof
- Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden and OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, and Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology - OncoRay Helmholtz-Zentrum Dresden-Rossendorf, Germany
| |
Collapse
|
3
|
Jia S, Chen Y, Cui J, Wang T, Lin CC. Relationship of weight loss to quality of life and symptom distress among postsurgical survivors of oesophageal cancer who received chemotherapy. Eur J Oncol Nurs 2023; 66:102370. [PMID: 37490815 DOI: 10.1016/j.ejon.2023.102370] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2023] [Revised: 06/06/2023] [Accepted: 06/09/2023] [Indexed: 07/27/2023]
Abstract
PURPOSE Weight loss is highly prevalent in oesophageal cancer survivors, who often experience disease-related or treatment-related symptoms and quality of life (QoL) impairment. This study aimed to explore the relationships among weight loss, symptom distress, and QoL postoperatively in patients with oesophageal cancer undergoing chemotherapy and to identify the factors influencing the QoL. METHODS We conducted a retrospective observational study with 101 patients and collected data on weight loss (percentage of total body mass loss), QoL (EORTC-QLQ-C30 and EORTC-QLQ-OES-18), and symptom distress (MDASI-GI-C). The associations among weight loss, QoL, and symptom distress were assessed using Pearson's correlation. Multiple linear regression analysis was used to identify independent factors influencing patients' QoL scores. RESULTS The distribution of weight loss of each stage in survivors of oesophageal cancer was 1.00% (SD: 2.48%), 4.69% (SD: 4.73%), 1.66% (SD: 5.37%), 2.83% (SD: 4.89%) respectively. The mean QoL score was 66.24 (SD 18.65). The participants' mean symptom severity and symptom interference scores were 3.30 (SD 1.74) and 2.76 (SD 1.90), respectively. Weight loss and symptom distress were negatively related to patients' QoL (p < 0.05, p < 0.01, respectively). Weight loss between 6 months before diagnosis and the time of diagnosis (p < 0.05) and symptom interference (p < 0.01) were independent predictors for the QoL. CONCLUSIONS This study suggests that oesophageal cancer survivors with larger weight reduction between 6 months before diagnosis and the time of diagnosis and more symptom distress have a worse QoL. Clinicians should focus more on patients' weight and symptom management to improve their QoL.
Collapse
Affiliation(s)
- Shumin Jia
- School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong
| | - Yanhong Chen
- Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| | - Jiqiang Cui
- Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| | - Tongyao Wang
- School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong
| | - Chia-Chin Lin
- School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong.
| |
Collapse
|
4
|
McGovern J, Delaney J, Forshaw MJ, McCabe G, Crumley AB, McIntosh D, Laird BJ, Horgan PG, McMillan DC, McSorley ST, Dolan RD. The relationship between computed tomography‐derived sarcopenia, cardiopulmonary exercise testing performance, systemic inflammation, and survival in good performance status patients with oesophago‐gastric cancer undergoing neoadjuvant treatment. JCSM CLINICAL REPORTS 2022. [DOI: 10.1002/crt2.57] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Affiliation(s)
- Josh McGovern
- Academic Unit of Surgery, School of Medicine University of Glasgow G31 2ER Glasgow Level 2, New Lister Building, Glasgow Royal Infirmary UK
| | - Jenna Delaney
- Academic Unit of Surgery, School of Medicine University of Glasgow G31 2ER Glasgow Level 2, New Lister Building, Glasgow Royal Infirmary UK
| | | | - Gerard McCabe
- Academic Unit of Surgery, School of Medicine University of Glasgow G31 2ER Glasgow Level 2, New Lister Building, Glasgow Royal Infirmary UK
| | - Andrew B. Crumley
- Academic Unit of Surgery, School of Medicine University of Glasgow G31 2ER Glasgow Level 2, New Lister Building, Glasgow Royal Infirmary UK
| | - David McIntosh
- Academic Unit of Surgery, School of Medicine University of Glasgow G31 2ER Glasgow Level 2, New Lister Building, Glasgow Royal Infirmary UK
| | - Barry J. Laird
- Institute of Genetics and Molecular Medicine University of Edinburgh Edinburgh UK
| | - Paul G. Horgan
- Academic Unit of Surgery, School of Medicine University of Glasgow G31 2ER Glasgow Level 2, New Lister Building, Glasgow Royal Infirmary UK
| | - Donald C. McMillan
- Academic Unit of Surgery, School of Medicine University of Glasgow G31 2ER Glasgow Level 2, New Lister Building, Glasgow Royal Infirmary UK
| | - Stephen T. McSorley
- Academic Unit of Surgery, School of Medicine University of Glasgow G31 2ER Glasgow Level 2, New Lister Building, Glasgow Royal Infirmary UK
| | - Ross D. Dolan
- Academic Unit of Surgery, School of Medicine University of Glasgow G31 2ER Glasgow Level 2, New Lister Building, Glasgow Royal Infirmary UK
| |
Collapse
|
5
|
Hoffmann L, Mortensen H, Shamshad M, Berbee M, Bizzocchi N, Bütof R, Canters R, Defraene G, Lykkegaard Ehmsen M, Fiorini F, Haustermans K, Hulley R, Korevaar EW, Clarke M, Makocki S, Muijs CT, Murray L, Nicholas O, Nordsmark M, Radhakrishna G, Thomas M, Troost EGC, Vilches-Freixas G, Visser S, Weber DC, Sloth Møller D. Treatment planning comparison in the PROTECT-trial randomising proton versus photon beam therapy in oesophageal cancer: results from eight european centres. Radiother Oncol 2022; 172:32-41. [PMID: 35513132 DOI: 10.1016/j.radonc.2022.04.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2022] [Revised: 04/06/2022] [Accepted: 04/28/2022] [Indexed: 10/18/2022]
Abstract
PURPOSE To compare dose distributions and robustness in treatment plans from eight European centres in preparation for the European randomized phase-III PROTECT-trial investigating the effect of proton therapy (PT) versus photon therapy (XT) for oesophageal cancer. MATERIALS AND METHODS All centres optimized one PT and one XT nominal plan using delineated 4DCT scans for four patients receiving 50.4Gy(RBE) in 28 fractions. Target volume receiving 95% of prescribed dose (V95%iCTVtotal) should be >99%. Robustness towards setup, range, and respiration was evaluated. The plans were recalculated on a surveillance 4DCT (sCT) acquired at fraction ten and robustness evaluation was performed to evaluate the effect of respiration and inter-fractional anatomical changes. RESULTS All PT and XT plans complied with V95%iCTVtotal>99% for the nominal plan and V95%iCTVtotal>97% for all respiratory and robustness scenarios. Lung and heart dose varied considerably between centres for both modalities. The difference in mean lung dose and mean heart dose between each pair of XT and PT plans was in median [range] 4.8Gy [1.1;7.6] and 8.4Gy [1.9;24.5], respectively. Patients B and C showed large inter-fractional anatomical changes on sCT. For patient B, the minimum V95%iCTVtotal in the worst-case robustness scenario was 45% and 94% for XT and PT, respectively. For patient C, the minimum V95%iCTVtotal was 57% and 72% for XT and PT, respectively. Patient A and D showed minor inter-fractional changes and the minimum V95%iCTVtotal was >85%. CONCLUSION Large variability in dose to the lungs and heart was observed for both modalities. Inter-fractional anatomical changes led to larger target dose deterioration for XT than PT plans.
Collapse
Affiliation(s)
- Lone Hoffmann
- Department of Medical Physics, Aarhus University Hospital, Denmark; Dept. of Clinical Medicine, Faculty of Health Sciences, Aarhus University, Aarhus, Denmark.
| | - Hanna Mortensen
- Danish Center for Particle Therapy, Aarhus University Hospital, Denmark
| | - Muhammad Shamshad
- Department of Medical Physics, Aarhus University Hospital, Denmark; Dept. of Clinical Medicine, Faculty of Health Sciences, Aarhus University, Aarhus, Denmark; Danish Center for Particle Therapy, Aarhus University Hospital, Denmark
| | - Maaike Berbee
- Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, The Netherlands
| | - Nicola Bizzocchi
- Center for Proton Therapy, Paul Scherrer Institut, Villigen, Switzerland
| | - Rebecca Bütof
- Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf, Dresden, Germany
| | - Richard Canters
- Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, The Netherlands
| | - Gilles Defraene
- KU Leuven - University of Leuven - Department of Oncology - Laboratory of Experimental Radiotherapy, Leuven, Belgium
| | | | | | - Karin Haustermans
- KU Leuven - University of Leuven - Department of Oncology - Laboratory of Experimental Radiotherapy, Leuven, Belgium; University Hospitals Leuven, Department of Radiation Oncology, Leuven, Belgium
| | - Ryan Hulley
- South West Wales Cancer Centre, Swansea University Board, UL AND Swansea University Medical School, United Kingdom
| | - Erik W Korevaar
- Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, The Netherlands
| | - Matthew Clarke
- The Christie NHS Foundation Trust, Manchester, United Kingdom
| | - Sebastian Makocki
- Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf, Dresden, Germany
| | - Christina T Muijs
- Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, The Netherlands
| | - Luke Murray
- Rutherford Cancer Centre, Shinfield, Reading, United Kingdom
| | - Owen Nicholas
- South West Wales Cancer Centre, Swansea University Board, UL AND Swansea University Medical School, United Kingdom
| | | | | | - Melissa Thomas
- KU Leuven - University of Leuven - Department of Oncology - Laboratory of Experimental Radiotherapy, Leuven, Belgium; University Hospitals Leuven, Department of Radiation Oncology, Leuven, Belgium
| | - Esther G C Troost
- Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf, Dresden, Germany; Institute of Radiooncology - OncoRay, Helmholtz-Zentrum Dresden-Rossendorf, Rossendorf, Germany; German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), Heidelberg, Germany; National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Helmholtz Association / Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany
| | - Gloria Vilches-Freixas
- Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, The Netherlands
| | - Sabine Visser
- Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, The Netherlands
| | - Damien C Weber
- Center for Proton Therapy, Paul Scherrer Institut, Villigen, Switzerland; Radiation Oncology Department, University Hospital Zurich, Zurich, Switzerland
| | - Ditte Sloth Møller
- Department of Medical Physics, Aarhus University Hospital, Denmark; Dept. of Clinical Medicine, Faculty of Health Sciences, Aarhus University, Aarhus, Denmark
| |
Collapse
|
6
|
Tsou YL, Lee JM, Tang CC. The Trajectory of Cancer-Related Fatigue and Its Associating Factors in Patients with Esophageal Cancer Receiving Treatments: A Prospective Longitudinal Study. Ann Surg Oncol 2022; 29:2784-2790. [PMID: 34997418 DOI: 10.1245/s10434-021-11294-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2021] [Accepted: 11/20/2021] [Indexed: 12/24/2022]
Abstract
BACKGROUND Cancer-related fatigue (CRF) is the most distressing symptom in the overall cancer population. For patients with esophageal cancer, CRF may even be harder to predict and control due to its complicated and prolonged treatment. Moreover, communication difficulties due to disease progression or treatment may further diminish esophageal cancer patients' ability to communicate about CRF. However, little research has addressed the trajectory and associating factors of CRF in this population, especially during the active treatment phase. The purpose of this study was (1) to evaluate and compare the level of CRF at three time points, namely before treatment, a month after concurrent chemoradiotherapy (CCRT), and a week after surgery, and (2) to identify associated factors of CRF. METHODS This prospective cohort study used a questionnaire to evaluate esophageal cancer patients' CRF at three time points. Repeated measures ANOVA and linear regression were used to analyze the data. RESULTS This study included 73 participants. The severity of all CRF aspects intensified significantly over the course of treatment, reaching the highest level after surgery (P < 0.001). Worries of physician invalidation at baseline (P < 0.05) and marital status associated with CRF after CCRT and after surgery. CONCLUSIONS This is the first study to demonstrate the relationship between CRF and physician invalidation. Clinicians must be aware of the intensifying trend of CRF and provide timely intervention when caring for patients with esophageal cancer during cancer treatment. Reducing the worries of physician invalidation may alleviate CRF.
Collapse
Affiliation(s)
- Yi-Ling Tsou
- School of Nursing, College of Medicine, National Taiwan University, Taipei, Taiwan.,Department of Nursing, National Taiwan University Hospital, Taipei, Taiwan
| | - Jang-Ming Lee
- Department of Surgery, College of Medicine, National Taiwan University, Taipei, Taiwan.,Division of Thoracic Surgery, Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan
| | - Chia-Chun Tang
- School of Nursing, College of Medicine, National Taiwan University, Taipei, Taiwan. .,Department of Nursing, National Taiwan University Hospital, Taipei, Taiwan.
| |
Collapse
|
7
|
Does it matter how we evaluate HRQOL? Longitudinal comparison of the EORTC QLQ-C30/QLQ-OG25 and FACT-E. J Cancer Surviv 2020; 15:641-650. [PMID: 33106994 DOI: 10.1007/s11764-020-00957-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2020] [Accepted: 10/10/2020] [Indexed: 01/22/2023]
Abstract
PURPOSE To determine whether EORTC QLQ-C30/QLQ-OG25 and FACT-E compared longitudinally provide similar reflections of health-related quality of life (HRQOL). METHODS Eighty-six esophageal cancer patients treated with curative intent, scheduled to complete both questionnaires at baseline and post-treatment time points until 36 months. A generalized estimating equation model utilizing a Gaussian family compared instruments longitudinally. The two-one-sided-test (TOST) method assessed equivalence between the instruments. RESULTS Trajectories for social domain and overall quality of life differed significantly between instruments. Also, FACT-G's functional well-being post-treatment returns to baseline 3-6 months earlier than the EORTC QLQ-C30's role functioning subscale, suggesting measurement of different components. Trajectories for physical and esophageal symptom subscales are similar and are deemed equivalent. Emotional domains are comparable and bear little resemblance to the physical domain trajectories indicating reflection of emotional experience rather than a physical proxy. EORTC QLQ-C30 subscales have a trajectory similar to its physical functioning scale except for the emotional and esophageal symptoms scales. Overall HRQOL in both instruments showed a consistent return to baseline/pre-treatment levels by 6 months post-treatment. CONCLUSIONS Overall HRQOL recovers earlier after curative-intent treatment than previously reported despite persistence of physical symptoms, with a consistent return to pre-treatment levels by 6 months after treatment. This supports the concept that HRQOL is not primarily defined by physical function. Based on this longitudinal comparison, FACT-E provides a more multidimensional assessment of HRQOL. IMPLICATIONS FOR CANCER SURVIVORS Curative intent treatment for esophageal cancer has adverse effects on HRQOL but despite intense treatment, overall HRQOL recovers within 6 months.
Collapse
|
8
|
Daundasekara SS, Arlinghaus KR, Johnston CA. Quality of Life: The Primary Goal of Lifestyle Intervention. Am J Lifestyle Med 2020; 14:267-270. [PMID: 32477025 PMCID: PMC7232900 DOI: 10.1177/1559827620907309] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
In much of lifestyle medicine, health-related quality of life (HRQoL) is a primary focus with the assumption that symptom reduction increases quality of life (QoL) in a more global sense. Lifestyle medicine research has shown that reducing symptoms increases the likelihood that QoL is improved. However, little information is available as to the impact of interventions when they are not effective in creating the desired healthy outcomes. It is possible that some lifestyle interventions have a negative impact on QoL, especially when a patient is not "successful" in reducing their symptomatology. Considering QoL from a broader perspective as an outcome in combination with traditional health outcomes may improve provider-patient rapport and empower patients to provide feedback on treatment, which, in turn, may improve overall treatment.
Collapse
Affiliation(s)
| | | | - Craig A. Johnston
- Department of Health and Human Performance, University of Houston, Houston, Texas
| |
Collapse
|
9
|
Götzl R, Sterzinger S, Semrau S, Vassos N, Hohenberger W, Grützmann R, Agaimy A, Arkudas A, Horch RE, Beier JP. Patient's quality of life after surgery and radiotherapy for extremity soft tissue sarcoma - a retrospective single-center study over ten years. Health Qual Life Outcomes 2019; 17:170. [PMID: 31703704 PMCID: PMC6842193 DOI: 10.1186/s12955-019-1236-4] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2019] [Accepted: 10/22/2019] [Indexed: 01/12/2023] Open
Abstract
Background and objectives The purpose of this study is to analyze major complication rates and different aspects of health-related quality of life (HRQoL) in extremity soft tissue sarcoma (STS) patients treated with or without radio (chemo) therapy and surgery. Methods We performed a retrospective analysis of all patients who underwent Extremity STS excision from 2004 to 2014 (182 patients included). Patients’ data were collected from patients’ records. HRQoL was assessed by using EORTC QLQ-C30. Results A total of 182 patients underwent sarcoma resection. After neoadjuvant radiochemotherapy (RCT), the major-complication rate amounted to 28% (vs. 7%, no radiotherapy, p < 0.001). Major-complication rates after adjuvant radiotherapy (RT) occurred in 8% (vs. 7%, no radiotherapy, p = 0.265). Comparison QoL scores between treating with neoadjuvant RCT or without RT revealed significant worse scores with neoadjuvant RCT. Further stratification of disease control of these patients showed significant reduced scores in the group of disease-free patients with neoadjuvant RCT compared to irradiated disease-free patients. Discussion To date, there have only been a few investigations of QoL in STS. Retrospective study on quality of life have limitations, like a lack of baseline evaluation of QoL. Patient candidated to radiation therapy could have had worse QoL baseline due to more advanced disease. Disease status of the patients who answered the questionnaires could have been an influence of QoL and we could show reduced scores in the group of disease-free patients with neoadjuvant RCT, but not for the patients with recurrence or metastasis, so it is very hard to discriminate whether radiation therapy could really have an impact or not. Conclusion This study might assist in further improving the understanding of QoL in STS patients and may animate for prospective studies examining the oncological therapies impact on HRQoL.
Collapse
Affiliation(s)
- Rebekka Götzl
- Department of Plastic and Hand Surgery, Comprehensive Cancer Center, Universitiy Hospital of Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany. .,Present Address: Department of Plastic Surgery, Hand and Burn Surgery, University Hospital of Aachen, RWTH University of Aachen, Aachen, Germany.
| | - Sebastian Sterzinger
- Department of Plastic and Hand Surgery, Comprehensive Cancer Center, Universitiy Hospital of Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany
| | - Sabine Semrau
- Department of Radiation Oncology, Comprehensive Cancer Center, University Hospital of Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany
| | - Nikolaos Vassos
- Department of Surgery, Comprehensive Cancer Center, University Hospital of Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany
| | - Werner Hohenberger
- Department of Surgery, Comprehensive Cancer Center, University Hospital of Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany
| | - Robert Grützmann
- Department of Surgery, Comprehensive Cancer Center, University Hospital of Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany
| | - Abbas Agaimy
- Department of Pathology, Comprehensive Cancer Center, University Hospital of Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany
| | - Andreas Arkudas
- Department of Plastic and Hand Surgery, Comprehensive Cancer Center, Universitiy Hospital of Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany
| | - Raymund E Horch
- Department of Plastic and Hand Surgery, Comprehensive Cancer Center, Universitiy Hospital of Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany
| | - Justus P Beier
- Department of Plastic and Hand Surgery, Comprehensive Cancer Center, Universitiy Hospital of Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany.,Present Address: Department of Plastic Surgery, Hand and Burn Surgery, University Hospital of Aachen, RWTH University of Aachen, Aachen, Germany
| |
Collapse
|
10
|
Baudry AS, Anota A, Mariette C, Bonnetain F, Renaud F, Piessen G, Christophe V. The role of trait emotional intelligence in quality of life, anxiety and depression symptoms after surgery for esophageal or gastric cancer: A French national database FREGAT. Psychooncology 2019; 28:799-806. [PMID: 30734393 DOI: 10.1002/pon.5023] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2018] [Revised: 02/04/2019] [Accepted: 02/05/2019] [Indexed: 12/12/2022]
Abstract
OBJECTIVE The main objective was to test the indirect effects of emotional competence (EC) after diagnosis (T1) on the health-related quality of life (HRQoL) after surgery (T2) of esogastric cancer patients via fewer anxiety and depression symptoms (T2). METHODS Data were collected from 30 French centers via the clinicobiological database French EsoGastric Tumors (FREGAT). Two hundred and twenty-eight participants completed a self-reported questionnaire at T1 and T2, assessing their EC (Profile of Emotional Competence (PEC)), HRQoL (EORTC Quality of Life Questionnaire-Core (QLQ-C30)), and anxiety and depression symptoms (Hospital Anxiety and Depression Scale (HADS)). Regression analyses were used to test the direct effects of intrapersonal and interpersonal EC on their anxiety/depression symptoms and HRQoL at T1 and T2. The PROCESS Macro in SPPS v.22 with bootstrap methods was used to test the indirect effects of intrapersonal and interpersonal EC at T1 on HRQoL at T2 via anxiety and depression symptoms. RESULTS EC predicted fewer anxiety and depression symptoms of patients at T1 and T2 and better HRQoL at T1. EC at T1 also predicted a better HRQoL at T2 via fewer anxiety and depression symptoms at T2. CONCLUSIONS Patients who tended to use their EC in daily life could be more effective in regulating the emotional impact of the cancer diagnosis and surgery. This explains why they reported fewer anxiety and depression symptoms, which in turn enabled a better perceived HRQoL after surgery. Therefore, reinforcing the use of patients' EC in daily life following their diagnosis could decrease their emotional distress and, in this way, improve their HRQoL in the preoperative and postoperative stages.
Collapse
Affiliation(s)
- Anne-Sophie Baudry
- Affective and Cognitive Sciences, University Lille, UMR CNRS 9193-SCALab, Villeneuve d'Ascq Cedex, France
| | - Amelie Anota
- Methodology and Quality of Life in Oncology Unit (INSERM UMR 1098), University Hospital of Besançon, Besançon, France
| | - Christophe Mariette
- Department of Digestive and Oncological Surgery, University Lille, Claude Huriez University Hospital, Lille Cedex, France.,Jean-Pierre Aubert Research Center, Neurosciences and Cancer, University Lille, UMR-S 1172-JPArc, Lille, France
| | - Franck Bonnetain
- Methodology and Quality of Life in Oncology Unit (INSERM UMR 1098), University Hospital of Besançon, Besançon, France
| | - Florence Renaud
- Jean-Pierre Aubert Research Center, Neurosciences and Cancer, University Lille, UMR-S 1172-JPArc, Lille, France.,Department of Pathology, Biology Pathology Center, University Lille, University Hospital, Lille, France
| | - Guillaume Piessen
- Department of Digestive and Oncological Surgery, University Lille, Claude Huriez University Hospital, Lille Cedex, France.,Jean-Pierre Aubert Research Center, Neurosciences and Cancer, University Lille, UMR-S 1172-JPArc, Lille, France
| | - Veronique Christophe
- Affective and Cognitive Sciences, University Lille, UMR CNRS 9193-SCALab, Villeneuve d'Ascq Cedex, France
| | | |
Collapse
|
11
|
Drummond RJ, Vass D, Wadhawan H, Craig CF, MacKay CK, Fullarton GM, Forshaw MJ. Routine pre- and post-neoadjuvant chemotherapy fitness testing is not indicated for oesophagogastric cancer surgery. Ann R Coll Surg Engl 2018; 100:515-519. [PMID: 29692190 PMCID: PMC6214048 DOI: 10.1308/rcsann.2018.0067] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/18/2018] [Indexed: 12/11/2022] Open
Abstract
Introduction There is a known correlation between anaerobic threshold (AT) during cardiopulmonary exercise testing and development of cardiopulmonary complications in high-risk patients undergoing oesophagogastric cancer surgery. This study aimed to assess the value of routine retesting following neoadjuvant chemotherapy. Methods Patients undergoing neoadjuvant chemotherapy with subsequent oesophagogastric cancer surgery with pre- and post-neoadjuvant chemotherapy cardiopulmonary exercise data were identified from a prospectively maintained database. Measured cardiopulmonary exercise variables included AT and maximum oxygen uptake at peak exercise (VO2 peak). Anaerobic threshold values within 1 ml/kg/minute were considered static. Patients were grouped into AT ranges of less than 9 ml/kg/minute, 9-11 ml/kg/minute and greater than 11 ml/kg/minute. Outcome measures were unplanned intensive care stay, postoperative cardiovascular morbidity and mortality. Results Between May 2008 and August 2017, 42 patients from 675 total resections were identified, with a mean age of 65 years (range 49-84 years). Mean pre-neoadjuvant chemotherapy AT was 11.07 ml/kg/minute (standard deviation, SD, 3.24 ml/kg/minute, range 4.6-19.3 ml/kg/minute) while post-neoadjuvant chemotherapy AT was 11.19 ml/kg/minute (SD 3.05 ml/kg/minute, range 5.2-18.1 ml/kg/minute). Mean pre-neoadjuvant chemotherapy VO2 peak was 17.13 ml/kg/minute, while post-chemotherapy this mean fell to 16.59 ml/kg/minute. Some 44.4% of patients with a pre-chemotherapy AT less than 9 ml/kg/minute developed cardiorespiratory complications compared with 42.2% of those whose AT was greater than 9 ml/kg/minute (P = 0.914); 63.6% of patients in the post-neoadjuvant chemotherapy group with an AT less than 9 ml/kg/minute developed cardiorespiratory complications. There was no correlation between direction of change in AT and outcome. Conclusion In our patient population, neoadjuvant chemotherapy does not appear to result in a significant mean reduction in cardiorespiratory fitness. Routine pre- and post-neoadjuvant chemotherapy cardiopulmonary exercise testing is currently not indicated; however, larger studies are required to demonstrate this conclusively.
Collapse
Affiliation(s)
- RJ Drummond
- Department of Upper Gastrointestinal Surgery, Queen Elizabeth University Hostpital, Glasgow, UK
| | - D Vass
- Department of Upper Gastrointestinal Surgery, Glasgow Royal Infirmary, Glasgow, UK
| | - H Wadhawan
- Department of Upper Gastrointestinal Surgery, Glasgow Royal Infirmary, Glasgow, UK
| | - CF Craig
- Department of Upper Gastrointestinal Surgery, Glasgow Royal Infirmary, Glasgow, UK
| | - CK MacKay
- Department of Upper Gastrointestinal Surgery, Glasgow Royal Infirmary, Glasgow, UK
| | - GM Fullarton
- Department of Upper Gastrointestinal Surgery, Glasgow Royal Infirmary, Glasgow, UK
| | - MJ Forshaw
- Department of Upper Gastrointestinal Surgery, Glasgow Royal Infirmary, Glasgow, UK
| |
Collapse
|
12
|
Noordman B, Verdam M, Lagarde S, Shapiro J, Hulshof M, van Berge Henegouwen M, Wijnhoven B, Nieuwenhuijzen G, Bonenkamp J, Cuesta M, Plukker J, Spillenaar Bilgen E, Steyerberg E, van der Gaast A, Sprangers M, van Lanschot J. Impact of neoadjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: results from the randomized CROSS trial. Ann Oncol 2018; 29:445-451. [DOI: 10.1093/annonc/mdx726] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
|
13
|
Noordman BJ, Verdam MG, Lagarde SM, Hulshof MC, van Hagen P, van Berge Henegouwen MI, Wijnhoven BP, van Laarhoven HW, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJM, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, Steyerberg EW, van der Gaast A, Sprangers MA, van Lanschot JJB. Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial. J Clin Oncol 2018; 36:268-275. [DOI: 10.1200/jco.2017.73.7718] [Citation(s) in RCA: 66] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
Purpose To compare pre-agreed health-related quality of life (HRQOL) domains in patients with esophageal or junctional cancer who received neoadjuvant chemoradiotherapy (nCRT) followed by surgery or surgery alone. Secondary aims were to examine the effect of nCRT on HRQOL before surgery and the effect of surgery on HRQOL. Patients and Methods Patients were randomly assigned to nCRT (carboplatin plus paclitaxel with concurrent 41.4-Gy radiotherapy) followed by surgery or surgery alone. HRQOL was measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–Core 30 (QLQ-C30) and –Oesophageal Cancer Module (QLQ-OES24) questionnaires pretreatment and at 3, 6, 9, and 12 months postoperatively. The nCRT group also received preoperative questionnaires. Physical functioning (PF; QLQ-C30) and eating problems (EA; QLQ-OES24) were chosen as predefined primary end points. Predefined secondary end points were global QOL (GQOL; QLQ-C30), fatigue (FA; QLQ-C30), and emotional problems (EM; QLQ-OES24). Results A total of 363 patients were analyzed. No statistically significant differences in postoperative HRQOL were found between treatment groups. In the nCRT group, PF, EA, GQOL, FA, and EM scores deteriorated 1 week after nCRT (Cohen’s d: −0.93, P < .001; 0.47, P < .001; −0.84, P < .001; 1.45, P < .001; and 0.32, P = .001, respectively). In both treatment groups, all end points declined 3 months postoperatively compared with baseline (Cohen’s d: −1.00, 0.33, −0.47, −0.34, and 0.33, respectively; all P < .001), followed by a continuous gradual improvement. EA, GQOL, and EM were restored to baseline levels during follow-up, whereas PF and FA remained impaired 1 year postoperatively (Cohen’s d: 0.52 and −0.53, respectively; both P < .001). Conclusion Although HRQOL declined during nCRT, no effect of nCRT was apparent on postoperative HRQOL compared with surgery alone. In addition to the improvement in survival, these findings support the view that nCRT according to the Chemoradiotherapy for Esophageal Cancer Followed by Surgery Study–regimen can be regarded as a standard of care.
Collapse
Affiliation(s)
- Bo Jan Noordman
- Bo Jan Noordman, Sjoerd M. Lagarde, Pieter van Hagen, Bas P.L. Wijnhoven, Fiebo J.W. ten Kate, Katharina Biermann, Caroline M. van Rij, Hugo W. Tilanus, Ewout W. Steyerberg, Ate van der Gaast, and J. Jan B. van Lanschot, Erasmus MC–University Medical Center Rotterdam; Mathilde G.E. Verdam, Maarten C.C.M. Hulshof, Mark I. van Berge Henegouwen, Hanneke W.M. van Laarhoven, Olivier R. Busch, Fiebo J.W. ten Kate, Cornelis J.A. Punt, and Mirjam A.G. Sprangers, Academic Medical Center; Miguel A. Cuesta, Henk M
| | - Mathilde G.E. Verdam
- Bo Jan Noordman, Sjoerd M. Lagarde, Pieter van Hagen, Bas P.L. Wijnhoven, Fiebo J.W. ten Kate, Katharina Biermann, Caroline M. van Rij, Hugo W. Tilanus, Ewout W. Steyerberg, Ate van der Gaast, and J. Jan B. van Lanschot, Erasmus MC–University Medical Center Rotterdam; Mathilde G.E. Verdam, Maarten C.C.M. Hulshof, Mark I. van Berge Henegouwen, Hanneke W.M. van Laarhoven, Olivier R. Busch, Fiebo J.W. ten Kate, Cornelis J.A. Punt, and Mirjam A.G. Sprangers, Academic Medical Center; Miguel A. Cuesta, Henk M
| | - Sjoerd M. Lagarde
- Bo Jan Noordman, Sjoerd M. Lagarde, Pieter van Hagen, Bas P.L. Wijnhoven, Fiebo J.W. ten Kate, Katharina Biermann, Caroline M. van Rij, Hugo W. Tilanus, Ewout W. Steyerberg, Ate van der Gaast, and J. Jan B. van Lanschot, Erasmus MC–University Medical Center Rotterdam; Mathilde G.E. Verdam, Maarten C.C.M. Hulshof, Mark I. van Berge Henegouwen, Hanneke W.M. van Laarhoven, Olivier R. Busch, Fiebo J.W. ten Kate, Cornelis J.A. Punt, and Mirjam A.G. Sprangers, Academic Medical Center; Miguel A. Cuesta, Henk M
| | - Maarten C.C.M. Hulshof
- Bo Jan Noordman, Sjoerd M. Lagarde, Pieter van Hagen, Bas P.L. Wijnhoven, Fiebo J.W. ten Kate, Katharina Biermann, Caroline M. van Rij, Hugo W. Tilanus, Ewout W. Steyerberg, Ate van der Gaast, and J. Jan B. van Lanschot, Erasmus MC–University Medical Center Rotterdam; Mathilde G.E. Verdam, Maarten C.C.M. Hulshof, Mark I. van Berge Henegouwen, Hanneke W.M. van Laarhoven, Olivier R. Busch, Fiebo J.W. ten Kate, Cornelis J.A. Punt, and Mirjam A.G. Sprangers, Academic Medical Center; Miguel A. Cuesta, Henk M
| | - Pieter van Hagen
- Bo Jan Noordman, Sjoerd M. Lagarde, Pieter van Hagen, Bas P.L. Wijnhoven, Fiebo J.W. ten Kate, Katharina Biermann, Caroline M. van Rij, Hugo W. Tilanus, Ewout W. Steyerberg, Ate van der Gaast, and J. Jan B. van Lanschot, Erasmus MC–University Medical Center Rotterdam; Mathilde G.E. Verdam, Maarten C.C.M. Hulshof, Mark I. van Berge Henegouwen, Hanneke W.M. van Laarhoven, Olivier R. Busch, Fiebo J.W. ten Kate, Cornelis J.A. Punt, and Mirjam A.G. Sprangers, Academic Medical Center; Miguel A. Cuesta, Henk M
| | - Mark I. van Berge Henegouwen
- Bo Jan Noordman, Sjoerd M. Lagarde, Pieter van Hagen, Bas P.L. Wijnhoven, Fiebo J.W. ten Kate, Katharina Biermann, Caroline M. van Rij, Hugo W. Tilanus, Ewout W. Steyerberg, Ate van der Gaast, and J. Jan B. van Lanschot, Erasmus MC–University Medical Center Rotterdam; Mathilde G.E. Verdam, Maarten C.C.M. Hulshof, Mark I. van Berge Henegouwen, Hanneke W.M. van Laarhoven, Olivier R. Busch, Fiebo J.W. ten Kate, Cornelis J.A. Punt, and Mirjam A.G. Sprangers, Academic Medical Center; Miguel A. Cuesta, Henk M
| | - Bas P.L. Wijnhoven
- Bo Jan Noordman, Sjoerd M. Lagarde, Pieter van Hagen, Bas P.L. Wijnhoven, Fiebo J.W. ten Kate, Katharina Biermann, Caroline M. van Rij, Hugo W. Tilanus, Ewout W. Steyerberg, Ate van der Gaast, and J. Jan B. van Lanschot, Erasmus MC–University Medical Center Rotterdam; Mathilde G.E. Verdam, Maarten C.C.M. Hulshof, Mark I. van Berge Henegouwen, Hanneke W.M. van Laarhoven, Olivier R. Busch, Fiebo J.W. ten Kate, Cornelis J.A. Punt, and Mirjam A.G. Sprangers, Academic Medical Center; Miguel A. Cuesta, Henk M
| | - Hanneke W.M. van Laarhoven
- Bo Jan Noordman, Sjoerd M. Lagarde, Pieter van Hagen, Bas P.L. Wijnhoven, Fiebo J.W. ten Kate, Katharina Biermann, Caroline M. van Rij, Hugo W. Tilanus, Ewout W. Steyerberg, Ate van der Gaast, and J. Jan B. van Lanschot, Erasmus MC–University Medical Center Rotterdam; Mathilde G.E. Verdam, Maarten C.C.M. Hulshof, Mark I. van Berge Henegouwen, Hanneke W.M. van Laarhoven, Olivier R. Busch, Fiebo J.W. ten Kate, Cornelis J.A. Punt, and Mirjam A.G. Sprangers, Academic Medical Center; Miguel A. Cuesta, Henk M
| | - Grard A.P. Nieuwenhuijzen
- Bo Jan Noordman, Sjoerd M. Lagarde, Pieter van Hagen, Bas P.L. Wijnhoven, Fiebo J.W. ten Kate, Katharina Biermann, Caroline M. van Rij, Hugo W. Tilanus, Ewout W. Steyerberg, Ate van der Gaast, and J. Jan B. van Lanschot, Erasmus MC–University Medical Center Rotterdam; Mathilde G.E. Verdam, Maarten C.C.M. Hulshof, Mark I. van Berge Henegouwen, Hanneke W.M. van Laarhoven, Olivier R. Busch, Fiebo J.W. ten Kate, Cornelis J.A. Punt, and Mirjam A.G. Sprangers, Academic Medical Center; Miguel A. Cuesta, Henk M
| | - Geke A.P. Hospers
- Bo Jan Noordman, Sjoerd M. Lagarde, Pieter van Hagen, Bas P.L. Wijnhoven, Fiebo J.W. ten Kate, Katharina Biermann, Caroline M. van Rij, Hugo W. Tilanus, Ewout W. Steyerberg, Ate van der Gaast, and J. Jan B. van Lanschot, Erasmus MC–University Medical Center Rotterdam; Mathilde G.E. Verdam, Maarten C.C.M. Hulshof, Mark I. van Berge Henegouwen, Hanneke W.M. van Laarhoven, Olivier R. Busch, Fiebo J.W. ten Kate, Cornelis J.A. Punt, and Mirjam A.G. Sprangers, Academic Medical Center; Miguel A. Cuesta, Henk M
| | - Johannes J. Bonenkamp
- Bo Jan Noordman, Sjoerd M. Lagarde, Pieter van Hagen, Bas P.L. Wijnhoven, Fiebo J.W. ten Kate, Katharina Biermann, Caroline M. van Rij, Hugo W. Tilanus, Ewout W. Steyerberg, Ate van der Gaast, and J. Jan B. van Lanschot, Erasmus MC–University Medical Center Rotterdam; Mathilde G.E. Verdam, Maarten C.C.M. Hulshof, Mark I. van Berge Henegouwen, Hanneke W.M. van Laarhoven, Olivier R. Busch, Fiebo J.W. ten Kate, Cornelis J.A. Punt, and Mirjam A.G. Sprangers, Academic Medical Center; Miguel A. Cuesta, Henk M
| | - Miguel A. Cuesta
- Bo Jan Noordman, Sjoerd M. Lagarde, Pieter van Hagen, Bas P.L. Wijnhoven, Fiebo J.W. ten Kate, Katharina Biermann, Caroline M. van Rij, Hugo W. Tilanus, Ewout W. Steyerberg, Ate van der Gaast, and J. Jan B. van Lanschot, Erasmus MC–University Medical Center Rotterdam; Mathilde G.E. Verdam, Maarten C.C.M. Hulshof, Mark I. van Berge Henegouwen, Hanneke W.M. van Laarhoven, Olivier R. Busch, Fiebo J.W. ten Kate, Cornelis J.A. Punt, and Mirjam A.G. Sprangers, Academic Medical Center; Miguel A. Cuesta, Henk M
| | - Reinoud J.B. Blaisse
- Bo Jan Noordman, Sjoerd M. Lagarde, Pieter van Hagen, Bas P.L. Wijnhoven, Fiebo J.W. ten Kate, Katharina Biermann, Caroline M. van Rij, Hugo W. Tilanus, Ewout W. Steyerberg, Ate van der Gaast, and J. Jan B. van Lanschot, Erasmus MC–University Medical Center Rotterdam; Mathilde G.E. Verdam, Maarten C.C.M. Hulshof, Mark I. van Berge Henegouwen, Hanneke W.M. van Laarhoven, Olivier R. Busch, Fiebo J.W. ten Kate, Cornelis J.A. Punt, and Mirjam A.G. Sprangers, Academic Medical Center; Miguel A. Cuesta, Henk M
| | - Olivier R. Busch
- Bo Jan Noordman, Sjoerd M. Lagarde, Pieter van Hagen, Bas P.L. Wijnhoven, Fiebo J.W. ten Kate, Katharina Biermann, Caroline M. van Rij, Hugo W. Tilanus, Ewout W. Steyerberg, Ate van der Gaast, and J. Jan B. van Lanschot, Erasmus MC–University Medical Center Rotterdam; Mathilde G.E. Verdam, Maarten C.C.M. Hulshof, Mark I. van Berge Henegouwen, Hanneke W.M. van Laarhoven, Olivier R. Busch, Fiebo J.W. ten Kate, Cornelis J.A. Punt, and Mirjam A.G. Sprangers, Academic Medical Center; Miguel A. Cuesta, Henk M
| | - Fiebo J.W. ten Kate
- Bo Jan Noordman, Sjoerd M. Lagarde, Pieter van Hagen, Bas P.L. Wijnhoven, Fiebo J.W. ten Kate, Katharina Biermann, Caroline M. van Rij, Hugo W. Tilanus, Ewout W. Steyerberg, Ate van der Gaast, and J. Jan B. van Lanschot, Erasmus MC–University Medical Center Rotterdam; Mathilde G.E. Verdam, Maarten C.C.M. Hulshof, Mark I. van Berge Henegouwen, Hanneke W.M. van Laarhoven, Olivier R. Busch, Fiebo J.W. ten Kate, Cornelis J.A. Punt, and Mirjam A.G. Sprangers, Academic Medical Center; Miguel A. Cuesta, Henk M
| | - Geert-Jan M. Creemers
- Bo Jan Noordman, Sjoerd M. Lagarde, Pieter van Hagen, Bas P.L. Wijnhoven, Fiebo J.W. ten Kate, Katharina Biermann, Caroline M. van Rij, Hugo W. Tilanus, Ewout W. Steyerberg, Ate van der Gaast, and J. Jan B. van Lanschot, Erasmus MC–University Medical Center Rotterdam; Mathilde G.E. Verdam, Maarten C.C.M. Hulshof, Mark I. van Berge Henegouwen, Hanneke W.M. van Laarhoven, Olivier R. Busch, Fiebo J.W. ten Kate, Cornelis J.A. Punt, and Mirjam A.G. Sprangers, Academic Medical Center; Miguel A. Cuesta, Henk M
| | - Cornelis J.A. Punt
- Bo Jan Noordman, Sjoerd M. Lagarde, Pieter van Hagen, Bas P.L. Wijnhoven, Fiebo J.W. ten Kate, Katharina Biermann, Caroline M. van Rij, Hugo W. Tilanus, Ewout W. Steyerberg, Ate van der Gaast, and J. Jan B. van Lanschot, Erasmus MC–University Medical Center Rotterdam; Mathilde G.E. Verdam, Maarten C.C.M. Hulshof, Mark I. van Berge Henegouwen, Hanneke W.M. van Laarhoven, Olivier R. Busch, Fiebo J.W. ten Kate, Cornelis J.A. Punt, and Mirjam A.G. Sprangers, Academic Medical Center; Miguel A. Cuesta, Henk M
| | - John Th.M. Plukker
- Bo Jan Noordman, Sjoerd M. Lagarde, Pieter van Hagen, Bas P.L. Wijnhoven, Fiebo J.W. ten Kate, Katharina Biermann, Caroline M. van Rij, Hugo W. Tilanus, Ewout W. Steyerberg, Ate van der Gaast, and J. Jan B. van Lanschot, Erasmus MC–University Medical Center Rotterdam; Mathilde G.E. Verdam, Maarten C.C.M. Hulshof, Mark I. van Berge Henegouwen, Hanneke W.M. van Laarhoven, Olivier R. Busch, Fiebo J.W. ten Kate, Cornelis J.A. Punt, and Mirjam A.G. Sprangers, Academic Medical Center; Miguel A. Cuesta, Henk M
| | - Henk M.W. Verheul
- Bo Jan Noordman, Sjoerd M. Lagarde, Pieter van Hagen, Bas P.L. Wijnhoven, Fiebo J.W. ten Kate, Katharina Biermann, Caroline M. van Rij, Hugo W. Tilanus, Ewout W. Steyerberg, Ate van der Gaast, and J. Jan B. van Lanschot, Erasmus MC–University Medical Center Rotterdam; Mathilde G.E. Verdam, Maarten C.C.M. Hulshof, Mark I. van Berge Henegouwen, Hanneke W.M. van Laarhoven, Olivier R. Busch, Fiebo J.W. ten Kate, Cornelis J.A. Punt, and Mirjam A.G. Sprangers, Academic Medical Center; Miguel A. Cuesta, Henk M
| | - Ernst J. Spillenaar Bilgen
- Bo Jan Noordman, Sjoerd M. Lagarde, Pieter van Hagen, Bas P.L. Wijnhoven, Fiebo J.W. ten Kate, Katharina Biermann, Caroline M. van Rij, Hugo W. Tilanus, Ewout W. Steyerberg, Ate van der Gaast, and J. Jan B. van Lanschot, Erasmus MC–University Medical Center Rotterdam; Mathilde G.E. Verdam, Maarten C.C.M. Hulshof, Mark I. van Berge Henegouwen, Hanneke W.M. van Laarhoven, Olivier R. Busch, Fiebo J.W. ten Kate, Cornelis J.A. Punt, and Mirjam A.G. Sprangers, Academic Medical Center; Miguel A. Cuesta, Henk M
| | - Herman van Dekken
- Bo Jan Noordman, Sjoerd M. Lagarde, Pieter van Hagen, Bas P.L. Wijnhoven, Fiebo J.W. ten Kate, Katharina Biermann, Caroline M. van Rij, Hugo W. Tilanus, Ewout W. Steyerberg, Ate van der Gaast, and J. Jan B. van Lanschot, Erasmus MC–University Medical Center Rotterdam; Mathilde G.E. Verdam, Maarten C.C.M. Hulshof, Mark I. van Berge Henegouwen, Hanneke W.M. van Laarhoven, Olivier R. Busch, Fiebo J.W. ten Kate, Cornelis J.A. Punt, and Mirjam A.G. Sprangers, Academic Medical Center; Miguel A. Cuesta, Henk M
| | - Maurice J.C. van der Sangen
- Bo Jan Noordman, Sjoerd M. Lagarde, Pieter van Hagen, Bas P.L. Wijnhoven, Fiebo J.W. ten Kate, Katharina Biermann, Caroline M. van Rij, Hugo W. Tilanus, Ewout W. Steyerberg, Ate van der Gaast, and J. Jan B. van Lanschot, Erasmus MC–University Medical Center Rotterdam; Mathilde G.E. Verdam, Maarten C.C.M. Hulshof, Mark I. van Berge Henegouwen, Hanneke W.M. van Laarhoven, Olivier R. Busch, Fiebo J.W. ten Kate, Cornelis J.A. Punt, and Mirjam A.G. Sprangers, Academic Medical Center; Miguel A. Cuesta, Henk M
| | - Tom Rozema
- Bo Jan Noordman, Sjoerd M. Lagarde, Pieter van Hagen, Bas P.L. Wijnhoven, Fiebo J.W. ten Kate, Katharina Biermann, Caroline M. van Rij, Hugo W. Tilanus, Ewout W. Steyerberg, Ate van der Gaast, and J. Jan B. van Lanschot, Erasmus MC–University Medical Center Rotterdam; Mathilde G.E. Verdam, Maarten C.C.M. Hulshof, Mark I. van Berge Henegouwen, Hanneke W.M. van Laarhoven, Olivier R. Busch, Fiebo J.W. ten Kate, Cornelis J.A. Punt, and Mirjam A.G. Sprangers, Academic Medical Center; Miguel A. Cuesta, Henk M
| | - Katharina Biermann
- Bo Jan Noordman, Sjoerd M. Lagarde, Pieter van Hagen, Bas P.L. Wijnhoven, Fiebo J.W. ten Kate, Katharina Biermann, Caroline M. van Rij, Hugo W. Tilanus, Ewout W. Steyerberg, Ate van der Gaast, and J. Jan B. van Lanschot, Erasmus MC–University Medical Center Rotterdam; Mathilde G.E. Verdam, Maarten C.C.M. Hulshof, Mark I. van Berge Henegouwen, Hanneke W.M. van Laarhoven, Olivier R. Busch, Fiebo J.W. ten Kate, Cornelis J.A. Punt, and Mirjam A.G. Sprangers, Academic Medical Center; Miguel A. Cuesta, Henk M
| | - Jannet C. Beukema
- Bo Jan Noordman, Sjoerd M. Lagarde, Pieter van Hagen, Bas P.L. Wijnhoven, Fiebo J.W. ten Kate, Katharina Biermann, Caroline M. van Rij, Hugo W. Tilanus, Ewout W. Steyerberg, Ate van der Gaast, and J. Jan B. van Lanschot, Erasmus MC–University Medical Center Rotterdam; Mathilde G.E. Verdam, Maarten C.C.M. Hulshof, Mark I. van Berge Henegouwen, Hanneke W.M. van Laarhoven, Olivier R. Busch, Fiebo J.W. ten Kate, Cornelis J.A. Punt, and Mirjam A.G. Sprangers, Academic Medical Center; Miguel A. Cuesta, Henk M
| | - Anna H.M. Piet
- Bo Jan Noordman, Sjoerd M. Lagarde, Pieter van Hagen, Bas P.L. Wijnhoven, Fiebo J.W. ten Kate, Katharina Biermann, Caroline M. van Rij, Hugo W. Tilanus, Ewout W. Steyerberg, Ate van der Gaast, and J. Jan B. van Lanschot, Erasmus MC–University Medical Center Rotterdam; Mathilde G.E. Verdam, Maarten C.C.M. Hulshof, Mark I. van Berge Henegouwen, Hanneke W.M. van Laarhoven, Olivier R. Busch, Fiebo J.W. ten Kate, Cornelis J.A. Punt, and Mirjam A.G. Sprangers, Academic Medical Center; Miguel A. Cuesta, Henk M
| | - Caroline M. van Rij
- Bo Jan Noordman, Sjoerd M. Lagarde, Pieter van Hagen, Bas P.L. Wijnhoven, Fiebo J.W. ten Kate, Katharina Biermann, Caroline M. van Rij, Hugo W. Tilanus, Ewout W. Steyerberg, Ate van der Gaast, and J. Jan B. van Lanschot, Erasmus MC–University Medical Center Rotterdam; Mathilde G.E. Verdam, Maarten C.C.M. Hulshof, Mark I. van Berge Henegouwen, Hanneke W.M. van Laarhoven, Olivier R. Busch, Fiebo J.W. ten Kate, Cornelis J.A. Punt, and Mirjam A.G. Sprangers, Academic Medical Center; Miguel A. Cuesta, Henk M
| | - Janny G. Reinders
- Bo Jan Noordman, Sjoerd M. Lagarde, Pieter van Hagen, Bas P.L. Wijnhoven, Fiebo J.W. ten Kate, Katharina Biermann, Caroline M. van Rij, Hugo W. Tilanus, Ewout W. Steyerberg, Ate van der Gaast, and J. Jan B. van Lanschot, Erasmus MC–University Medical Center Rotterdam; Mathilde G.E. Verdam, Maarten C.C.M. Hulshof, Mark I. van Berge Henegouwen, Hanneke W.M. van Laarhoven, Olivier R. Busch, Fiebo J.W. ten Kate, Cornelis J.A. Punt, and Mirjam A.G. Sprangers, Academic Medical Center; Miguel A. Cuesta, Henk M
| | - Hugo W. Tilanus
- Bo Jan Noordman, Sjoerd M. Lagarde, Pieter van Hagen, Bas P.L. Wijnhoven, Fiebo J.W. ten Kate, Katharina Biermann, Caroline M. van Rij, Hugo W. Tilanus, Ewout W. Steyerberg, Ate van der Gaast, and J. Jan B. van Lanschot, Erasmus MC–University Medical Center Rotterdam; Mathilde G.E. Verdam, Maarten C.C.M. Hulshof, Mark I. van Berge Henegouwen, Hanneke W.M. van Laarhoven, Olivier R. Busch, Fiebo J.W. ten Kate, Cornelis J.A. Punt, and Mirjam A.G. Sprangers, Academic Medical Center; Miguel A. Cuesta, Henk M
| | - Ewout W. Steyerberg
- Bo Jan Noordman, Sjoerd M. Lagarde, Pieter van Hagen, Bas P.L. Wijnhoven, Fiebo J.W. ten Kate, Katharina Biermann, Caroline M. van Rij, Hugo W. Tilanus, Ewout W. Steyerberg, Ate van der Gaast, and J. Jan B. van Lanschot, Erasmus MC–University Medical Center Rotterdam; Mathilde G.E. Verdam, Maarten C.C.M. Hulshof, Mark I. van Berge Henegouwen, Hanneke W.M. van Laarhoven, Olivier R. Busch, Fiebo J.W. ten Kate, Cornelis J.A. Punt, and Mirjam A.G. Sprangers, Academic Medical Center; Miguel A. Cuesta, Henk M
| | - Ate van der Gaast
- Bo Jan Noordman, Sjoerd M. Lagarde, Pieter van Hagen, Bas P.L. Wijnhoven, Fiebo J.W. ten Kate, Katharina Biermann, Caroline M. van Rij, Hugo W. Tilanus, Ewout W. Steyerberg, Ate van der Gaast, and J. Jan B. van Lanschot, Erasmus MC–University Medical Center Rotterdam; Mathilde G.E. Verdam, Maarten C.C.M. Hulshof, Mark I. van Berge Henegouwen, Hanneke W.M. van Laarhoven, Olivier R. Busch, Fiebo J.W. ten Kate, Cornelis J.A. Punt, and Mirjam A.G. Sprangers, Academic Medical Center; Miguel A. Cuesta, Henk M
| | - Mirjam A.G. Sprangers
- Bo Jan Noordman, Sjoerd M. Lagarde, Pieter van Hagen, Bas P.L. Wijnhoven, Fiebo J.W. ten Kate, Katharina Biermann, Caroline M. van Rij, Hugo W. Tilanus, Ewout W. Steyerberg, Ate van der Gaast, and J. Jan B. van Lanschot, Erasmus MC–University Medical Center Rotterdam; Mathilde G.E. Verdam, Maarten C.C.M. Hulshof, Mark I. van Berge Henegouwen, Hanneke W.M. van Laarhoven, Olivier R. Busch, Fiebo J.W. ten Kate, Cornelis J.A. Punt, and Mirjam A.G. Sprangers, Academic Medical Center; Miguel A. Cuesta, Henk M
| | - J. Jan B. van Lanschot
- Bo Jan Noordman, Sjoerd M. Lagarde, Pieter van Hagen, Bas P.L. Wijnhoven, Fiebo J.W. ten Kate, Katharina Biermann, Caroline M. van Rij, Hugo W. Tilanus, Ewout W. Steyerberg, Ate van der Gaast, and J. Jan B. van Lanschot, Erasmus MC–University Medical Center Rotterdam; Mathilde G.E. Verdam, Maarten C.C.M. Hulshof, Mark I. van Berge Henegouwen, Hanneke W.M. van Laarhoven, Olivier R. Busch, Fiebo J.W. ten Kate, Cornelis J.A. Punt, and Mirjam A.G. Sprangers, Academic Medical Center; Miguel A. Cuesta, Henk M
| |
Collapse
|
14
|
Chen CY, Hsieh VCR, Chang CH, Chen PR, Liang WM, Pan SC, Shieh SH. Impacts of treatments on the quality of life among esophageal squamous cell carcinoma patients. Dis Esophagus 2017; 30:1-8. [PMID: 28859389 DOI: 10.1093/dote/dox061] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/15/2016] [Accepted: 05/18/2017] [Indexed: 12/11/2022]
Abstract
This study aims to investigate the effects of treatments on the quality of life for patients with esophageal squamous cell carcinoma patients diagnosed at early and late stages. From a medical center in central Taiwan, patients who had been diagnosed with esophageal squamous cell carcinoma from February 2007 and March 2011 were recruited. Using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and the Quality of Life Questionnaire Oesophageal 18 (QLQ-OES18), quality of life scores for 105 esophageal squamous cell carcinoma patients were obtained and assessed. Multivariate analysis was performed on the quality of life scores after stratification by cancer stage. Among early-stage esophageal squamous cell carcinoma patients, those received only surgery (S-only) performed better in physical and social functioning compared with patients who underwent surgery and concurrent chemoradiotherapy (S+CCRT) (β = 9.0, P = 0.03; β = 12.1, P = 0.04, respectively). For those that received only concurrent chemoradiotherapy (CCRT-only), they performed worse in role and emotional functioning relative to S+CCRT patients (β = -17.2, P = 0.02; β = -15.7, P = 0.05, respectively). Among late-stage patients, CCRT-only treatment gave insignificantly better global health status and functional scale scores and less severe symptoms compared to the S+CCRT option. Better functional scores and less aggravated symptoms are observed in early-stage esophageal squamous cell carcinoma patients who received surgery-only treatment relative to those that underwent both surgery and chemoradiotherapy. For late-stage esophageal cancer patients, the measured difference of quality of life is not significant between CCRT-only and S+CCRT treatments.
Collapse
Affiliation(s)
- C-Y Chen
- Institute of Medicine, Department of Surgery, Chung Shan Medical University, Chung Shan Medical University Hospital, Taichung, Taiwan
| | - V C-R Hsieh
- Department of Health Services Administration, China Medical University, Taichung, Taiwan
| | - C-H Chang
- Department of Physical Medicine and Rehabilitation, and the Beuhler Center on Aging, Health & Society, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.,Rehabilitation Institute of Chicago, Chicago, Illinois, USA
| | - P-R Chen
- Division of Thoracic Surgery, China Medical University and Hospital, Taichung, Taiwan
| | - W-M Liang
- Graduate Institute of Biostatistics, China Medical University, Taichung, Taiwan
| | - S-C Pan
- Institute of Occupational Medicine and Industrial Hygiene, National Taiwan University, Taipei, Taiwan
| | - S-H Shieh
- Department of Health Services Administration, China Medical University, Taichung, Taiwan.,Department of Nursing, China Medical University Hospital, Taichung, Taiwan
| |
Collapse
|
15
|
Dai Z, Lang W, Yang H, Tian J, Sun W, Pekbay B, Lin Y, Wang M, Cui B, Yang S, Li H, Luo L, Guo H, Zhang L. Validation of EORTC QLQ-OES18 for Chinese patients with esophageal cancer. Dis Esophagus 2017; 30:1-7. [PMID: 28859386 DOI: 10.1093/dote/dox046] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/09/2016] [Accepted: 04/06/2017] [Indexed: 02/06/2023]
Abstract
The aim of this study is to evaluate the reliability, validity, and acceptability of the Chinese version of the EORTC QLQ-OES18 in patients with esophageal cancer. The questionnaire was translated according to the guideline of the EORTC. One hundred and forty-nine patients with esophageal cancer from Tianjin Medical University Cancer Institute and Hospital completed the Karnofsky performance scale (KPS) and the simplified Chinese EORTC QLQ-C30/OES18 scales during July 2013 to January 2014. The results were statistically analyzed by Cronbach's α coefficient, Spearman correlation test with multiple strengthen analysis, and Wilcoxon Rank Sum test. The internal consistency (Cronbach's α coefficient) of all four scales (dysphagia, eating, reflux, and pain) was 0.689-0.822, which were satisfactory or near satisfactory. The absolute values of correlation of each scale between EORTC QLQ-OES18 and EORTC QLQ-C30 were 0.002-0.750 while there was no significant difference between groups divided by KPS scores. We confirmed the Chinese version of EORTC QLQ-OES18 appears to be a reliable, valid, and acceptable instrument for measuring the health-related quality of life of patients with esophageal cancer in mainland China.
Collapse
Affiliation(s)
- Z Dai
- Key Laboratory of Cancer Prevention and Therapy, Department of Endoscopy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China
| | - W Lang
- Tianjin Medical University, Tianjin, China
| | - H Yang
- Tianjin Medical University, Tianjin, China
| | - J Tian
- Xiangya School of Medicine, Central South University, Changsha, China
| | - W Sun
- Tianjin Medical University, Tianjin, China
| | - B Pekbay
- Erasmus University Rotterdam, Rotterdam, Netherlands
| | - Y Lin
- Tianjin Medical University, Tianjin, China
| | - M Wang
- Tianjin Medical University, Tianjin, China
| | - B Cui
- Tianjin Medical University, Tianjin, China
| | - S Yang
- Xiangya School of Medicine, Central South University, Changsha, China
| | - H Li
- Department of Esophageal Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
| | - L Luo
- Department of Radiation Oncology, Tumor Hospital, Xiangya School of Medicine of Central South University, Changsha, China
| | - H Guo
- Tianjin Medical University, Tianjin, China
| | - L Zhang
- Key Laboratory of Cancer Prevention and Therapy, Tianjin Lung Cancer Center, Department of Thoracic Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China
| |
Collapse
|
16
|
Straatman J, Joosten PJM, Terwee CB, Cuesta MA, Jansma EP, van der Peet DL. Systematic review of patient-reported outcome measures in the surgical treatment of patients with esophageal cancer. Dis Esophagus 2016; 29:760-772. [PMID: 26471471 DOI: 10.1111/dote.12405] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Esophageal cancer is currently the eighth most common cancer worldwide. Improvements in operative techniques and neoadjuvant therapies have led to improved outcomes. Resection of the esophagus carries a high risk of severe complications and has a negative impact on health-related quality of life (QOL). The aim of this study was to assess which patient-reported outcome measures (PROMs) are used to measure QOL after esophagectomy for cancer. A comprehensive search of original articles was conducted investigating QOL after surgery for esophageal carcinoma. Two authors independently selected relevant articles, conducted clinical appraisal, and extracted data (PJ and JS). Out of 5893 articles, 58 studies were included, consisting of 41 prospective and 17 retrospective cohort studies, including a total of 6964 patients. These studies included 11 different PROMs. The existing PROMs could be divided into generic, symptom-specific, and disease-specific questionnaires. The European Organisation for Research and Treatment of Cancer (EORTC) QOL Questionnaire Core 30 (QLQ C-30) along with the EORTC QLQ-OESophagus module OES18 was the most widely used; in 42 and 32 studies, respectively. The EORTC and the Functional Assessment of Cancer Therapy (FACT) questionnaires use an oncological module and an organ-specific module. One validation study was available, which compared the FACT and EORTC, showing moderate to poor correlation between the questionnaires. A great variety of PROMs are being used in the measurement of QOL after surgery for esophageal cancer. A questionnaire with a general module along with a disease-specific module for assessment of QOL of different treatment modalities seem to be the most desirable, such as the EORTC and the FACT with their specific modules (EORTC QLQ-OES18 and FACT-E). Both are developed in different treatment modalities, such as in surgical patients. With regard to reproducibility of current results, the EORTC is recommended.
Collapse
Affiliation(s)
- J Straatman
- Departments of Gastrointestinal Surgery, VU University Medical Center, Amsterdam, The Netherlands.
| | - P J M Joosten
- Departments of Gastrointestinal Surgery, VU University Medical Center, Amsterdam, The Netherlands
| | - C B Terwee
- Departments of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, The Netherlands
| | - M A Cuesta
- Departments of Gastrointestinal Surgery, VU University Medical Center, Amsterdam, The Netherlands
| | - E P Jansma
- Medical library, VU University Medical Center, Amsterdam, The Netherlands
| | - D L van der Peet
- Departments of Gastrointestinal Surgery, VU University Medical Center, Amsterdam, The Netherlands
| |
Collapse
|
17
|
Di Pardo BJ, Bronson NW, Diggs BS, Thomas CR, Hunter JG, Dolan JP. The Global Burden of Esophageal Cancer: A Disability-Adjusted Life-Year Approach. World J Surg 2016; 40:395-401. [PMID: 26630937 DOI: 10.1007/s00268-015-3356-2] [Citation(s) in RCA: 59] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
INTRODUCTION Esophageal cancer is the eighth most common cancer worldwide and the sixth leading cause of cancer-related deaths. As a significant cause of morbidity and mortality, its burden on society has yet to be fully characterized. The aim of this study is to examine its global burden through estimation of the disability-adjusted life years (DALYs) attributable to it. METHODS Global incidence and mortality estimates for esophageal cancer were obtained from the International Agency for Research on Cancer GLOBOCAN 2008 database. DALYs were calculated, using methodology established by the World Health Organization. RESULTS In 2008, 3,955,919 DALYs were attributed to esophageal cancer, at a global rate of 0.58 DALYs per 1000 people annually. Years of life lost (YLL) accounted for 96.8 % of DALYs, while years lived with disability (YLD) accounted for 3.2 %. 83.8 % of the global DALYs occurred in less-developed countries, with most accrued in Eastern Asia, comprising 50.9 % of the total. The highest rate of DALY accrual was in Southern Africa, at 1.62 DALYs per 1000 people annually. CONCLUSIONS A substantial number of years of life were lost or affected by esophageal cancer worldwide in 2008, with the burden resting disproportionately on less-developed countries. Geographically, the greatest burden is in Eastern Asia. The vast majority of DALYs were due to YLL, rather than YLD, indicating the need to focus resources on disease prevention and early detection. Our findings provide an additional basis upon which to formulate global priorities for interventions that affect DALY reduction in esophageal cancer.
Collapse
Affiliation(s)
- Benjamin J Di Pardo
- Division of Gastrointestinal and General Surgery, Department of Surgery, Digestive Health Center, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Mailcode L223A, Portland, OR, 97239, USA
| | - Nathan W Bronson
- Division of Gastrointestinal and General Surgery, Department of Surgery, Digestive Health Center, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Mailcode L223A, Portland, OR, 97239, USA
| | - Brian S Diggs
- Division of Gastrointestinal and General Surgery, Department of Surgery, Digestive Health Center, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Mailcode L223A, Portland, OR, 97239, USA
| | - Charles R Thomas
- Department of Radiation Medicine, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
| | - John G Hunter
- Division of Gastrointestinal and General Surgery, Department of Surgery, Digestive Health Center, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Mailcode L223A, Portland, OR, 97239, USA
| | - James P Dolan
- Division of Gastrointestinal and General Surgery, Department of Surgery, Digestive Health Center, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Mailcode L223A, Portland, OR, 97239, USA.
| |
Collapse
|
18
|
Comparative Effectiveness of Esophagectomy Versus Endoscopic Treatment for Esophageal High-grade Dysplasia. Ann Surg 2016; 263:719-26. [PMID: 26672723 DOI: 10.1097/sla.0000000000001387] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
OBJECTIVE The purpose of this study is to determine the comparative effectiveness of esophagectomy versus endoscopic mucosal resection followed by radiofrequency ablation (EMR-RFA) for the treatment of Barrett esophagus with high-grade dysplasia (HGD). BACKGROUND HGD of the esophagus may be managed by surgical resection or EMR-RFA. National guidelines suggest that EMR-RFA is effective at eradicating HGD. The comparative effectiveness and cost-effectiveness of EMR-RFA versus esophagectomy for HGD remains unclear. METHODS A decision-analysis model was constructed to represent 3 management strategies for HGD: (1) esophagectomy, (2) EMR-RFA, and (3) endoscopic surveillance. Estimates for model variables were obtained from literature review, and costs were estimated from Medicare fee schedules. Costs and utilities were discounted at an annual rate of 3%. The baseline model was adjusted for alternative age groups and high-risk dysplastic variants. One-way and multivariable probabilistic sensitivity analyses were conducted. RESULTS For a 65-year-old patient, compared to esophagectomy, EMR-RFA yields equivalent utility (11.5 vs 11.4 discounted quality-adjusted life years) with lower total cost ($52.5K vs $74.3K) over the first 20 years. Dominance of EMR-RFA over esophagectomy persists for all age groups. Patients with diffuse or ulcerated HGD are more effectively treated with esophagectomy. Model outcomes are sensitive to estimated rates of disease progression and postintervention utility parameters. CONCLUSIONS Existing evidence supports EMR-RFA over esophagectomy for the treatment of esophageal HGD. Long-term outcomes and more definitive quality-of-life studies for both interventions are crucial to better inform decision-making.
Collapse
|
19
|
Tarricone R, Abu Koush D, Nyanzi-Wakholi B, Medina-Lara A. A systematic literature review of the economic implications of chemotherapy-induced diarrhea and its impact on quality of life. Crit Rev Oncol Hematol 2016; 99:37-48. [DOI: 10.1016/j.critrevonc.2015.12.012] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2015] [Revised: 12/22/2015] [Accepted: 12/22/2015] [Indexed: 12/27/2022] Open
|
20
|
Cancer survivorship: long-term side-effects of anticancer treatments of gastrointestinal cancer. Curr Opin Oncol 2016; 27:351-7. [PMID: 26049277 DOI: 10.1097/cco.0000000000000203] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
PURPOSE OF REVIEW Surveillance of patients with a history of cancer is a frequent practice in oncology. However, it is often aimed at the early diagnosis of relapse and tends to underestimate the evaluation and care of factors impairing quality of life (QoL). Among these, long-term toxicities of anticancer treatments are one of the major threats to a complete physical and psychosocial recovery. We aimed to review the relevant literature on long-term side-effects of treatment in gastrointestinal cancers. RECENT FINDINGS We focused on esophageal, gastric, pancreatic, liver and colorectal cancers. A significant fraction of patients treated for these cancers suffer with some form of late toxicity from surgery, radiotherapy or chemotherapy. Prompt evaluation and management is of the utmost importance in reducing the impact of these symptoms on QoL. SUMMARY The knowledge of the reviewed data should encourage a multidisciplinary approach to surveillance and convince clinicians of the comprehensive role of survivorship care.
Collapse
|
21
|
Cheville AL, Alberts SR, Rummans TA, Basford JR, Lapid MI, Sloan JA, Satele DV, Clark MM. Improving Adherence to Cancer Treatment by Addressing Quality of Life in Patients With Advanced Gastrointestinal Cancers. J Pain Symptom Manage 2015; 50:321-7. [PMID: 25975643 PMCID: PMC5557268 DOI: 10.1016/j.jpainsymman.2015.03.005] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/02/2014] [Revised: 03/02/2015] [Accepted: 03/12/2015] [Indexed: 01/14/2023]
Abstract
CONTEXT Many patients with potentially curable cancer do not complete their prescribed treatment regimens because of the toxicity. There is evidence that the common endpoints of many of these toxicities are amenable to quality of life (QOL)-directed interventions. OBJECTIVES This study was conducted to determine the effect of a multidisciplinary QOL-directed intervention on patients' adherence to planned chemoradiation (CR) regimens. METHODS The results of two randomized controlled trials that used the same QOL intervention were pooled to form a cohort of 61 patients with advanced localized gastrointestinal cancer. Of these 61 subjects, 29 participated in six to eight bi- to triweekly sessions that included exercise, education, and relaxation, and 32 received usual medical care. The primary endpoint was completion of their prescribed CR regimens. Secondary outcomes included hospitalization during CR, rates of adverse postoperative events, and complete pathological response in those undergoing neoadjuvant therapy. RESULTS Significantly, more members of the intervention than the control group completed their planned CR regimens (77.8 vs. 38.2%, P = 0.003). More participants in the control (n = 14) than the intervention (n = 5) group (P = 0.063) required hospitalization. Among those undergoing neoadjuvant CR, those in the intervention group were significantly more likely to complete CR as planned (81.0% vs. 37.5%, P = 0.005) and less likely to be hospitalized (14.3% vs. 50.0%, P = 0.011). CONCLUSION A structured multidisciplinary QOL-directed intervention delivered to patients undergoing CR may increase the proportion of patients who complete CR as planned and reduce unplanned hospitalizations. Utilization is an important outcome in QOL-directed intervention trials.
Collapse
Affiliation(s)
- Andrea L Cheville
- Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, Minnesota, USA.
| | - Steven R Alberts
- Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA
| | - Teresa A Rummans
- Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA
| | - Jeffrey R Basford
- Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, Minnesota, USA
| | - Maria I Lapid
- Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA
| | - Jeff A Sloan
- Department of Health Service Research, Mayo Clinic, Rochester, Minnesota, USA
| | - Daniel V Satele
- Department of Health Service Research, Mayo Clinic, Rochester, Minnesota, USA
| | - Matthew M Clark
- Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA
| |
Collapse
|
22
|
Beisland E, Aarstad HJ, Aarstad AKH, Bakke A, Bostad L, Beisland C. Development of a disease-specific health-related quality of life (HRQoL) questionnaire intended to be used in conjunction with the general European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) in renal cell carcinoma patients. Acta Oncol 2015; 55:349-56. [PMID: 26251300 DOI: 10.3109/0284186x.2015.1063776] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
BACKGROUND Studying health-related quality of life (HRQoL) following cancer treatment has become part of a growing number of standardized treatment protocols. The European Organization for Research and Treatment of Cancer (EORTC) has developed HRQoL questionnaires aimed at cancer patients. A disease-specific part is not available for renal cell carcinoma (RCC) patients, and the present aim was to develop an EORTC-compatible RCC-specific HRQoL questionnaire. MATERIAL AND METHODS In total 413 RCC patients were treated with radical or partial nephrectomies in Western Norway during the period from 1997 to 2010. Three hundred and nine patients with histologically proven cancer were still alive at the inclusion time point and 185 RCC patients (71% response rate) returned the questionnaires. We determined HRQoL by the EORTC-QLQ C30 questionnaire. We also asked 13 candidates questions aimed at constituting a disease-specific part. Furthermore, we tested parts of personality by the Eysenck Personality Inventory and coping by the COPE questionnaire. Given tumor treatment, TNM stage, alcohol consumption level and smoking levels were also determined from the hospital records. RESULTS A factor analysis showed that five factors were formed: one general symptomatic, one general functional, one with disease-specific questions (flank pain, blood in the urine, flank edema, urinary tract infection), one about sexuality and one about weight loss or gain. Ten RCC-specific HRQoL questions were derived from a factor analysis, including four questions related particularly to pain, mobility and social functioning, also representing a short version of the EORTC C30. The psychometric properties and the relation to other psychological and clinical variables were further determined to be satisfactory. CONCLUSIONS The suggested disease-specific EORTC-QLQ-style RCC10 version adds important information about the HRQoL of RCC patients, providing additional apparent value to the general questionnaire and personality variables, as well as being psychometrically satisfactory. The questionnaire has a potential as a "stand alone" HRQoL questionnaire among RCC patients.
Collapse
Affiliation(s)
- Elisabeth Beisland
- Faculty of Health and Social Sciences, Bergen University College, Bergen, Norway
- Department of Clinical Medicine, University of Bergen, Bergen, Norway
| | - Hans J. Aarstad
- Department of Otolaryngology/Head and Neck Surgery, Haukeland University Hospital, Bergen, Norway
- Department of Clinical Medicine, University of Bergen, Bergen, Norway
| | - Anne K. H. Aarstad
- Department of Otolaryngology/Head and Neck Surgery, Haukeland University Hospital, Bergen, Norway
- Haraldsplass Deaconal University College, Bergen, Norway
| | - August Bakke
- Department of Urology, Haukeland University Hospital, Bergen, Norway
- Department of Clinical Medicine, University of Bergen, Bergen, Norway
| | - Leif Bostad
- Department of Pathology, Haukeland University Hospital, Bergen, Norway
- Department of Clinical Medicine, University of Bergen, Bergen, Norway
| | - Christian Beisland
- Department of Urology, Haukeland University Hospital, Bergen, Norway
- Department of Clinical Medicine, University of Bergen, Bergen, Norway
| |
Collapse
|
23
|
Hendijani F. Human mesenchymal stromal cell therapy for prevention and recovery of chemo/radiotherapy adverse reactions. Cytotherapy 2015; 17:509-25. [DOI: 10.1016/j.jcyt.2014.10.015] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2014] [Revised: 10/07/2014] [Accepted: 10/27/2014] [Indexed: 12/21/2022]
|
24
|
Chang D, Church J. Evaluating the health-related quality of life of esophageal cancer patients. Pract Radiat Oncol 2014; 4:181-186. [DOI: 10.1016/j.prro.2013.07.009] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2013] [Revised: 06/05/2013] [Accepted: 07/10/2013] [Indexed: 11/27/2022]
|
25
|
Macefield RC, Jacobs M, Korfage IJ, Nicklin J, Whistance RN, Brookes ST, Sprangers MAG, Blazeby JM. Developing core outcomes sets: methods for identifying and including patient-reported outcomes (PROs). Trials 2014; 15:49. [PMID: 24495582 PMCID: PMC3916696 DOI: 10.1186/1745-6215-15-49] [Citation(s) in RCA: 122] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2013] [Accepted: 01/17/2014] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND Synthesis of patient-reported outcome (PRO) data is hindered by the range of available PRO measures (PROMs) composed of multiple scales and single items with differing terminology and content. The use of core outcome sets, an agreed minimum set of outcomes to be measured and reported in all trials of a specific condition, may improve this issue but methods to select core PRO domains from the many available PROMs are lacking. This study examines existing PROMs and describes methods to identify health domains to inform the development of a core outcome set, illustrated with an example. METHODS Systematic literature searches identified validated PROMs from studies evaluating radical treatment for oesophageal cancer. PROM scale/single item names were recorded verbatim and the frequency of similar names/scales documented. PROM contents (scale components/single items) were examined for conceptual meaning by an expert clinician and methodologist and categorised into health domains. A patient advocate independently checked this categorisation. RESULTS Searches identified 21 generic and disease-specific PROMs containing 116 scales and 32 single items with 94 different verbatim names. Identical names for scales were repeatedly used (for example, 'physical function' in six different measures) and others were similar (overlapping face validity) although component items were not always comparable. Based on methodological, clinical and patient expertise, 606 individual items were categorised into 32 health domains. CONCLUSION This study outlines a methodology for identifying candidate PRO domains from existing PROMs to inform a core outcome set to use in clinical trials.
Collapse
Affiliation(s)
- Rhiannon C Macefield
- School of Social and Community Medicine, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol BS8 2PS, UK
| | - Marc Jacobs
- Department of Medical Psychology, Academic Medical Center/University of Amsterdam, Meibergdreef 5, Amsterdam NL 1105 AZ, Netherlands
| | - Ida J Korfage
- Department of Public Health, Erasmus MC, P.O. Box 2040, Rotterdam NL 3000 CA, Netherlands
| | - Joanna Nicklin
- Division of Surgery, Head and Neck, University Hospitals Bristol NHS Foundation Trust, Level 3, Dolphin House, Bristol Royal Infirmary, Marlborough Street, Bristol BS2 8HW, UK
| | - Robert N Whistance
- School of Social and Community Medicine, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol BS8 2PS, UK
| | - Sara T Brookes
- School of Social and Community Medicine, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol BS8 2PS, UK
| | - Mirjam AG Sprangers
- Department of Medical Psychology, Academic Medical Center/University of Amsterdam, Meibergdreef 5, Amsterdam NL 1105 AZ, Netherlands
| | - Jane M Blazeby
- School of Social and Community Medicine, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol BS8 2PS, UK
- Division of Surgery, Head and Neck, University Hospitals Bristol NHS Foundation Trust, Level 3, Dolphin House, Bristol Royal Infirmary, Marlborough Street, Bristol BS2 8HW, UK
| |
Collapse
|
26
|
|
27
|
Bronson NW, Luna RA, Hunter JG. Tailoring esophageal cancer surgery. Semin Thorac Cardiovasc Surg 2013; 24:275-87. [PMID: 23465676 DOI: 10.1053/j.semtcvs.2012.11.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/20/2012] [Indexed: 12/15/2022]
Abstract
Esophageal cancer is a significant source of major mortality worldwide and is increasing dramatically in incidence. Without treatment this disease leads rapidly to death, but intervention also carries significant risk, so a carefully tailored approach must be used to maximize oncological efficacy while minimizing the negative consequences of intervention. Careful patient selection based on histologic and anatomic staging, consideration of each patient's clinical variables, appropriately timing chemo- and radiation therapy, and minimizing the morbidity of surgical intervention may significantly improve a patient's chances of surviving this disease, but each must be carefully orchestrated with a tailored approach to treatment. This review will serve as a guide to tailoring surgery for esophageal cancer.
Collapse
Affiliation(s)
- Nathan W Bronson
- Department of Surgery, Oregon Health & Science University, Portland, Oregon 97239, USA
| | | | | |
Collapse
|
28
|
Markar SR, Bodnar A, Rosales J, Song G, Low DE. The impact of neoadjuvant chemoradiotherapy on perioperative outcomes, tumor pathology, and survival in clinical stage II and III esophageal cancer. Ann Surg Oncol 2013; 20:3935-41. [PMID: 23892525 DOI: 10.1245/s10434-013-3137-9] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2013] [Indexed: 12/30/2022]
Abstract
BACKGROUND The purpose of this study was to evaluate the impact of neoadjuvant chemoradiotherapy (NCR) on perioperative outcomes, tumor pathology, and survival following surgical resection of clinical stage II and III esophageal cancer. METHODS Patients undergoing esophagectomy for clinical stage II and III cancer were divided into two groups: those who received NCR and those who underwent primary surgery (1991-2011). RESULTS A total of 173 (50.9%) of 340 stage II/III patients received NCR, 108 (31.8%) patients underwent primary surgery, and 59 (17.4%) underwent neoadjuvant chemotherapy followed by surgery. Patients who received NCR were younger but had a similar Charlson comorbidity index and incidence of adenocarcinoma. There were no differences between groups in the incidence of complications, in-hospital mortality, and ICU stay, but patients who received NCR demonstrated a reduced length of hospital stay. NCR was associated with a reduced the incidence of positive pathological lymph node status and positive resection margin (3.1 vs. 21.1%) in stage III esophageal cancer. No overall survival benefit was seen with use of NCR, although a nonsignificant improvement in survival of 22 months (p = 0.06) was noted in patients with adenocarcinoma. Negative resection margin was associated with an improved survival in both stage II and III patients. CONCLUSIONS This study highlights the importance of planning operations to optimize the opportunity to provide negative surgical resection margins and to identify patients not responding to NCR to allow them to proceed directly to surgery. Additional assessment of the effect of NCR on patients with adenocarcinoma is warranted.
Collapse
Affiliation(s)
- Sheraz R Markar
- Department of Thoracic Surgery, Virginia Mason Medical Center, Seattle, WA, USA,
| | | | | | | | | |
Collapse
|
29
|
Beisland E, Aarstad AKH, Osthus AA, Aarstad HJ. Stability of distress and health-related quality of life as well as relation to neuroticism, coping and TNM stage in head and neck cancer patients during follow-up. Acta Otolaryngol 2013; 133:209-17. [PMID: 23176066 DOI: 10.3109/00016489.2012.720032] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
CONCLUSION Distress and to some extent health-related quality of life (HRQoL) in head and neck squamous cell carcinoma (HNSCC) patients was found to be stable during follow-up. About one-third of the distress and HRQoL variances were accounted for in the present investigation with one-third from T stage, one-third directly from neuroticism and one-third from neuroticism via choice of coping response. In addition, choice of coping response predicted directly 5% of the HRQoL variance. OBJECTIVE To investigate the stability of distress and HRQoL as related to neuroticism and choice of coping response in HNSCC patients during a follow-up period of 4 years. METHODS We determined distress by the general health questionnaire (GHQ), HRQoL, personality by the Eysenck Personality Questionnaire (EPQ) and choice of coping response. All patients younger than 78 years with new HNSCC in Western Norway in the period 1992-2001 following successful treatment were interviewed. We determined GHQ and EORTC QLQ C30/H&N35 a second time after 4 years. RESULTS The GHQ scores were stable, whereas the HRQoL sum scores declined slightly (p < 0.001). The GHQ and the HRQoL scores were predicted by neuroticism, avoidant coping pattern, T stage and smoking history, but primarily H&N-specific HRQoL was predicted by treatment-derived factors.
Collapse
Affiliation(s)
- Elisabeth Beisland
- Department of Otolaryngology/Head and Neck Surgery, Haukeland University Hospital
| | | | | | | |
Collapse
|
30
|
Effects of a self-care education program on quality of life after surgery in patients with esophageal cancer. Gastroenterol Nurs 2012; 35:332-40. [PMID: 23018169 DOI: 10.1097/sga.0b013e3182605f86] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
In recent years, the number of quality-of-life (QOL) studies on patients with esophageal cancer has increased; however, the number of studies related to the effects of self-care education programs on QOL of these patients is scarce. This article reports on the effects of a self-care education program on QOL for patients with esophageal cancer in Babol, Iran. The quasi-experimental study had a convenience sample of 105 patients with esophageal cancer referred to oncology centers in Babol City. A quasi-random allocation technique was used to divide the sample into experimental (n = 55) and control (n = 50) groups. Appropriate instruments were used to measure QOL (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-30 and Quality of Life Questionnaire-Oesophageal 18). Questionnaires were completed by the respondents before and 3 months after implementing the educational program that consisted of group discussion, lectures, and pamphlets. There was no significant difference between QOL mean score of both groups before the intervention; however, after implementing the educational program, the QOL significantly improved in the experimental group (p = .001), whereas QOL decreased in the controls. We conclude that self-care education programs have positive effects on the QOL of patients with esophageal cancer. Planning and implementing such self-care education programs, when patients are under treatment, can help them improve their QOL.
Collapse
|
31
|
Systematic review reveals limitations of studies evaluating health-related quality of life after potentially curative treatment for esophageal cancer. Qual Life Res 2012; 22:1787-803. [DOI: 10.1007/s11136-012-0290-8] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/03/2012] [Indexed: 12/21/2022]
|
32
|
|
33
|
Stauder MC, Romero Y, Kabat B, Atherton PJ, Geno D, Deschamps C, Jatoi A, Sloan JA, Botros M, Jung KW, Arora AS, Miller RC. Overall survival and self-reported fatigue in patients with esophageal cancer. Support Care Cancer 2012; 21:511-9. [DOI: 10.1007/s00520-012-1537-1] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2012] [Accepted: 06/25/2012] [Indexed: 11/12/2022]
|
34
|
Head and neck specific Health Related Quality of Life scores predict subsequent survival in successfully treated head and neck cancer patients: a prospective cohort study. Oral Oncol 2012; 47:974-9. [PMID: 21856209 DOI: 10.1016/j.oraloncology.2011.07.010] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2011] [Revised: 07/08/2011] [Accepted: 07/12/2011] [Indexed: 11/23/2022]
Abstract
To examine the survival prediction of head and neck (H&N) Health Related Quality of Life (HRQoL) scores among successfully treated and cognitive functioning H&N squamous cell carcinoma (HNSCC) patients. Through structured interviews, self-reported questionnaires were given to 139 successfully treated HNSCC patients, 67 ± 32 months following diagnosis. HRQoL-scores, measured with the EORTC QLQ-H&N35 inventory, self-reported levels of neuroticism, avoidance focused coping, coping by suppression of competing activity, alcohol consumption, smoking status, and heart and lung disease, as well as gender, age, TNM-stage, and tumor site were determined. The mean observation period was 75 ± 4 months among the survivors. Twenty-four deaths were observed. A EORTC QLQ-H&N 35 sum score, including a dichotomized version (HR 2.73-3.67), was predictive of survival, both directly and after adjustment for all of the above mentioned variables. The H&N HRQoL indices "feeling ill", "sexuality", "open mouth", "swallowing", and "pain" specifically predicted survival. The dichotomized H&N HRQoL sum score compared the 4th upper quartile to the three lower quartiles, and a cut off value of 28.5 was designated. Analyses demonstrated that a high risk group with 33% mortality may include only one quarter of the patient population as opposed to 12.5% mortality among the other patients. Our findings indicate a unique survival prediction from EORTC QLQ-H&N 35 sum scores in successfully treated HNSCC patients. HRQoL scores, in particular, related to oral health, predicted survival. Furthermore, HRQoL-scores may be a screening tool for identifying patients with high mortality risk.
Collapse
|
35
|
Follow-up and Quality of Life after Esophagectomy. Updates Surg 2012. [DOI: 10.1007/978-88-470-2330-7_19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
36
|
Aarstad AKH, Beisland E, Aarstad HJ. Personality, choice of coping and T stage predict level of distress in head and neck cancer patients during follow-up. Eur Arch Otorhinolaryngol 2011; 269:2121-8. [PMID: 22200985 DOI: 10.1007/s00405-011-1884-4] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2011] [Accepted: 12/09/2011] [Indexed: 01/23/2023]
Abstract
The aim of the present study was to investigate to what extent TNM stage, treatment level, personality, choice of coping, mood and health-related quality of life (HRQoL) scores predicted distress as measured by general health questionnaire (GHQ) in successfully treated head and neck squamous cell carcinoma (HNSCC) patients. All patients younger than 80 years who had been diagnosed with HNSCC in western Norway in the period from 1992 to 1997, and who had survived until 1999, were sampled. Ninety-six patients (90% response rate) were included 48 ± 2 months after diagnosis. We determined personality by the Eysenck personality inventory, coping by the COPE questionnaire; HRQoL by EORTC QLQ questionnaire; and mood by Beck depression inventory (BDI). Fifty-five of 58 eligible patients were interviewed a second time 47 ± 1 months after the first interview where neuroticism and GHQ-30 questionnaires were answered. Both HRQoL [explained variance (EV), 9-40%] and BDI (EV 26-30%) scores predicted the GHQ scores. Numerical T stage was inversely associated with GHQ scores (EV ~10%). High neuroticism generally predicted high GHQ scores (EV 16-28%). Avoidance focused, problem focused, drinking to cope predicted GHQ scores (EV 8-14%) and high alcohol consumption (EV ~8%) predicted GHQ scores. The present association pattern could still be shown when adjusted for gender, age and educational level when studied by multiple regression analyses. In conclusion, lowered HRQoL, low mood, a high T stage, high alcohol consumption, high neuroticism, coping by avoidance and coping by problem solving directly predicted worse distress as measured by high GHQ scores, whereas neuroticism was also associated with GHQ through choice of coping.
Collapse
Affiliation(s)
- Anne K H Aarstad
- Department of Surgical Sciences, Faculty of Medicine, University of Bergen, 5021 Bergen, Norway.
| | | | | |
Collapse
|
37
|
Osthus A, Aarstad A, Olofsson J, Aarstad H. Health-Related Quality of Life Scores in long-term head and neck cancer survivors predict subsequent survival: a prospective cohort study. Clin Otolaryngol 2011; 36:361-8. [DOI: 10.1111/j.1749-4486.2011.02342.x] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|